Point of Care Hematology Diagnostics Market By Test Type (Complete Blood Count (CBC), Coagulation Testing, Hemoglobin Testing and Anemia Diagnosis, Others), By Mode of Prescription (Prescription based product, OTC based product), By End User (Diagnostic Centers, Hospitals, Blood Banks and Transfusion Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2030
The global point of care hematology diagnostics market was valued at $2.4 billion in 2023, and is projected to reach $3.6 billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030.
Point-of-care (POC) hematology diagnostics refer to diagnostic tests for blood disorders that are conducted outside of a laboratory, typically in hospitals, clinics, or even at home. These tests are designed to provide quick and accurate results, allowing for faster decision-making and treatment, particularly in emergency or outpatient settings. This reduces reliance on centralized laboratory tests, leading to faster diagnosis, improved patient care, and better overall outcomes. The ability to deliver real-time results helps healthcare providers address critical health issues promptly and efficiently.
The point of care hematology diagnostics market growth is primarily driven by increase in demand for rapid, accurate, and accessible diagnostic solutions that are used at or near the site of patient care. In addition, rise in geriatric population and surge in chronic disease cases have heightened the need for real-time diagnostic tools that offer quick results, enabling immediate clinical decisions, which is expected to drive the point-of-care (POC) hematology diagnostics market growth. The shift toward decentralized healthcare systems, particularly in developing regions, propels the adoption of portable hematology analyzers that reduce dependency on centralized laboratory infrastructure. In addition, technological advancements in microfluidics, lab-on-a-chip platforms, and biosensor integration have significantly improved the accuracy, portability, and affordability of POC hematology devices. These innovations make diagnostics more accessible in remote, rural, and underserved areas, thus addressing the unmet needs of large patient populations. Another contributing factor is the surge in preference for home-based and self-monitoring diagnostic kits, driven by increase in consumer awareness and the trend toward personalized healthcare.
However, the high cost of advanced POC hematology devices limits the adoption of POC testing products, especially in low-resource settings and smaller healthcare facilities. In addition, concerns regarding the accuracy and reliability of POC testing compared to centralized laboratory methods remain a barrier, as false results can lead to misdiagnosis or delayed treatment thereby restricting the point of care hematology diagnostics market growth.
On the other hand, advancements in microfluidics and smartphone-integrated diagnostic technologies are paving the way for next-generation POC hematology devices that provide faster, more accurate, and multiplexed testing capabilities, which provide lucrative opportunity for market growth. For instance, in April 2022, Sysmex Corporation introduced the XQ-320, a three-part differential automated hematology analyzer suitable for physician's office laboratories and complex facilities.
Segment Review
The point of care hematology diagnostics marketis segmented on the basis of test type, mode of prescription, end user, and region. By test type, the market is classified into complete blood count (CBC), coagulation testing, hemoglobin testing & anemia diagnosis, and others. By mode of prescription, the market is segregated into prescription-based products and OTC based products. By end user, the market is fragmented into diagnostic centers, hospitals, blood banks & transfusion centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, Hungary, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and the rest of LAMEA).
Key Findings
By test type, the complete blood count (CBC) segment dominated the point of care hematology diagnostics marketin 2023.
By mode of prescription, the prescription-based product segment dominated the point of care hematology diagnostics marketin 2023.
By end user, the hospitals segment dominated the market share in 2023.
By region, North America dominated thepoint of care hematology diagnosticsmarket size in terms of revenue in 2023.
Competition Analysis
Major key players that operate in the global point of care hematology diagnostics market are HORIBA, Ltd., Bio-Rad Laboratories, Inc., Sysmex Corporation, Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Shenzhen Mindray, Medical Electronics Co., Ltd., EKF Diagnostics Holdings plc., Madison Industries, F. HoffmannLa Roche Ltd., and SoulBrain Holdings Co Ltd.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the point of care hematology diagnostics market analysis from 2023 to 2030 to identify the prevailing point of care hematology diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the point of care hematology diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global point of care hematology diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
By Test Type
Point-of-care (POC) hematology diagnostics refer to diagnostic tests for blood disorders that are conducted outside of a laboratory, typically in hospitals, clinics, or even at home. These tests are designed to provide quick and accurate results, allowing for faster decision-making and treatment, particularly in emergency or outpatient settings. This reduces reliance on centralized laboratory tests, leading to faster diagnosis, improved patient care, and better overall outcomes. The ability to deliver real-time results helps healthcare providers address critical health issues promptly and efficiently.
The point of care hematology diagnostics market growth is primarily driven by increase in demand for rapid, accurate, and accessible diagnostic solutions that are used at or near the site of patient care. In addition, rise in geriatric population and surge in chronic disease cases have heightened the need for real-time diagnostic tools that offer quick results, enabling immediate clinical decisions, which is expected to drive the point-of-care (POC) hematology diagnostics market growth. The shift toward decentralized healthcare systems, particularly in developing regions, propels the adoption of portable hematology analyzers that reduce dependency on centralized laboratory infrastructure. In addition, technological advancements in microfluidics, lab-on-a-chip platforms, and biosensor integration have significantly improved the accuracy, portability, and affordability of POC hematology devices. These innovations make diagnostics more accessible in remote, rural, and underserved areas, thus addressing the unmet needs of large patient populations. Another contributing factor is the surge in preference for home-based and self-monitoring diagnostic kits, driven by increase in consumer awareness and the trend toward personalized healthcare.
However, the high cost of advanced POC hematology devices limits the adoption of POC testing products, especially in low-resource settings and smaller healthcare facilities. In addition, concerns regarding the accuracy and reliability of POC testing compared to centralized laboratory methods remain a barrier, as false results can lead to misdiagnosis or delayed treatment thereby restricting the point of care hematology diagnostics market growth.
On the other hand, advancements in microfluidics and smartphone-integrated diagnostic technologies are paving the way for next-generation POC hematology devices that provide faster, more accurate, and multiplexed testing capabilities, which provide lucrative opportunity for market growth. For instance, in April 2022, Sysmex Corporation introduced the XQ-320, a three-part differential automated hematology analyzer suitable for physician's office laboratories and complex facilities.
Segment Review
The point of care hematology diagnostics marketis segmented on the basis of test type, mode of prescription, end user, and region. By test type, the market is classified into complete blood count (CBC), coagulation testing, hemoglobin testing & anemia diagnosis, and others. By mode of prescription, the market is segregated into prescription-based products and OTC based products. By end user, the market is fragmented into diagnostic centers, hospitals, blood banks & transfusion centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, Hungary, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and the rest of LAMEA).
Key Findings
By test type, the complete blood count (CBC) segment dominated the point of care hematology diagnostics marketin 2023.
By mode of prescription, the prescription-based product segment dominated the point of care hematology diagnostics marketin 2023.
By end user, the hospitals segment dominated the market share in 2023.
By region, North America dominated thepoint of care hematology diagnosticsmarket size in terms of revenue in 2023.
Competition Analysis
Major key players that operate in the global point of care hematology diagnostics market are HORIBA, Ltd., Bio-Rad Laboratories, Inc., Sysmex Corporation, Danaher Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Shenzhen Mindray, Medical Electronics Co., Ltd., EKF Diagnostics Holdings plc., Madison Industries, F. HoffmannLa Roche Ltd., and SoulBrain Holdings Co Ltd.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the point of care hematology diagnostics market analysis from 2023 to 2030 to identify the prevailing point of care hematology diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the point of care hematology diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global point of care hematology diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Reimbursement Scenario
By Test Type
- Complete Blood Count (CBC)
- Coagulation Testing
- Hemoglobin Testing and Anemia Diagnosis
- Others
- Diagnostic Centers
- Hospitals
- Blood Banks and Transfusion Centers
- Others
- Prescription based product
- OTC based product
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Hungary
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- HORIBA, Ltd.
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- EKF Diagnostics Holdings plc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Abbott Laboratories
- Madison Industries
- SoulBrain Holdings Co Ltd
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of hematological disorders
3.4.1.2. Technological advancements in point-of-care (POC) hematology
3.4.1.3. Surge in adoption of point of care testing
3.4.2. Restraints
3.4.2.1. Lack of skilled personnel in underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Expansion of point of care testing in developing countries
CHAPTER 4: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Complete Blood Count (CBC)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Coagulation Testing
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Hemoglobin Testing and Anemia Diagnosis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription based product
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. OTC based product
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic Centers
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospitals
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Blood Banks and Transfusion Centers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Test Type
7.2.3. Market size and forecast, by Mode of Prescription
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Test Type
7.2.5.1.2. Market size and forecast, by Mode of Prescription
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Test Type
7.2.5.2.2. Market size and forecast, by Mode of Prescription
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Test Type
7.2.5.3.2. Market size and forecast, by Mode of Prescription
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Test Type
7.3.3. Market size and forecast, by Mode of Prescription
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Test Type
7.3.5.1.2. Market size and forecast, by Mode of Prescription
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Test Type
7.3.5.2.2. Market size and forecast, by Mode of Prescription
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Test Type
7.3.5.3.2. Market size and forecast, by Mode of Prescription
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Test Type
7.3.5.4.2. Market size and forecast, by Mode of Prescription
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Test Type
7.3.5.5.2. Market size and forecast, by Mode of Prescription
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Hungary
7.3.5.6.1. Market size and forecast, by Test Type
7.3.5.6.2. Market size and forecast, by Mode of Prescription
7.3.5.6.3. Market size and forecast, by End User
7.3.5.7. Rest of Europe
7.3.5.7.1. Market size and forecast, by Test Type
7.3.5.7.2. Market size and forecast, by Mode of Prescription
7.3.5.7.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Test Type
7.4.3. Market size and forecast, by Mode of Prescription
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Test Type
7.4.5.1.2. Market size and forecast, by Mode of Prescription
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Test Type
7.4.5.2.2. Market size and forecast, by Mode of Prescription
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Test Type
7.4.5.3.2. Market size and forecast, by Mode of Prescription
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Test Type
7.4.5.4.2. Market size and forecast, by Mode of Prescription
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Test Type
7.4.5.5.2. Market size and forecast, by Mode of Prescription
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Test Type
7.4.5.6.2. Market size and forecast, by Mode of Prescription
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Test Type
7.5.3. Market size and forecast, by Mode of Prescription
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Test Type
7.5.5.1.2. Market size and forecast, by Mode of Prescription
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Test Type
7.5.5.2.2. Market size and forecast, by Mode of Prescription
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Test Type
7.5.5.3.2. Market size and forecast, by Mode of Prescription
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Test Type
7.5.5.4.2. Market size and forecast, by Mode of Prescription
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Sysmex Corporation
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Danaher Corporation
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Thermo Fisher Scientific Inc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Abbott Laboratories
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. EKF Diagnostics Holdings plc.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. HORIBA, Ltd.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Bio-Rad Laboratories, Inc.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Madison Industries
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.11. SoulBrain Holdings Co Ltd
9.11.1. Company overview
9.11.2. Key executives
9.11.3. Company snapshot
9.11.4. Operating business segments
9.11.5. Product portfolio
9.11.6. Business performance
9.11.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of hematological disorders
3.4.1.2. Technological advancements in point-of-care (POC) hematology
3.4.1.3. Surge in adoption of point of care testing
3.4.2. Restraints
3.4.2.1. Lack of skilled personnel in underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Expansion of point of care testing in developing countries
CHAPTER 4: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Complete Blood Count (CBC)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Coagulation Testing
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Hemoglobin Testing and Anemia Diagnosis
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription based product
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. OTC based product
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic Centers
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospitals
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Blood Banks and Transfusion Centers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Test Type
7.2.3. Market size and forecast, by Mode of Prescription
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Test Type
7.2.5.1.2. Market size and forecast, by Mode of Prescription
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Test Type
7.2.5.2.2. Market size and forecast, by Mode of Prescription
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Test Type
7.2.5.3.2. Market size and forecast, by Mode of Prescription
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Test Type
7.3.3. Market size and forecast, by Mode of Prescription
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Test Type
7.3.5.1.2. Market size and forecast, by Mode of Prescription
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Test Type
7.3.5.2.2. Market size and forecast, by Mode of Prescription
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Test Type
7.3.5.3.2. Market size and forecast, by Mode of Prescription
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Test Type
7.3.5.4.2. Market size and forecast, by Mode of Prescription
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Test Type
7.3.5.5.2. Market size and forecast, by Mode of Prescription
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Hungary
7.3.5.6.1. Market size and forecast, by Test Type
7.3.5.6.2. Market size and forecast, by Mode of Prescription
7.3.5.6.3. Market size and forecast, by End User
7.3.5.7. Rest of Europe
7.3.5.7.1. Market size and forecast, by Test Type
7.3.5.7.2. Market size and forecast, by Mode of Prescription
7.3.5.7.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Test Type
7.4.3. Market size and forecast, by Mode of Prescription
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Test Type
7.4.5.1.2. Market size and forecast, by Mode of Prescription
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Test Type
7.4.5.2.2. Market size and forecast, by Mode of Prescription
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Test Type
7.4.5.3.2. Market size and forecast, by Mode of Prescription
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Test Type
7.4.5.4.2. Market size and forecast, by Mode of Prescription
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Test Type
7.4.5.5.2. Market size and forecast, by Mode of Prescription
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Test Type
7.4.5.6.2. Market size and forecast, by Mode of Prescription
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Test Type
7.5.3. Market size and forecast, by Mode of Prescription
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Test Type
7.5.5.1.2. Market size and forecast, by Mode of Prescription
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Test Type
7.5.5.2.2. Market size and forecast, by Mode of Prescription
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Test Type
7.5.5.3.2. Market size and forecast, by Mode of Prescription
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Test Type
7.5.5.4.2. Market size and forecast, by Mode of Prescription
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Sysmex Corporation
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Danaher Corporation
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Thermo Fisher Scientific Inc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Abbott Laboratories
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. EKF Diagnostics Holdings plc.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. HORIBA, Ltd.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Bio-Rad Laboratories, Inc.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Madison Industries
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.11. SoulBrain Holdings Co Ltd
9.11.1. Company overview
9.11.2. Key executives
9.11.3. Company snapshot
9.11.4. Operating business segments
9.11.5. Product portfolio
9.11.6. Business performance
9.11.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 02. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COMPLETE BLOOD COUNT (CBC), BY REGION, 2023-2030 ($MILLION)
TABLE 03. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2023-2030 ($MILLION)
TABLE 04. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HEMOGLOBIN TESTING AND ANEMIA DIAGNOSIS, BY REGION, 2023-2030 ($MILLION)
TABLE 05. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2030 ($MILLION)
TABLE 06. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 07. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR PRESCRIPTION BASED PRODUCT, BY REGION, 2023-2030 ($MILLION)
TABLE 08. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTC BASED PRODUCT, BY REGION, 2023-2030 ($MILLION)
TABLE 09. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 10. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2023-2030 ($MILLION)
TABLE 11. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023-2030 ($MILLION)
TABLE 12. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR BLOOD BANKS AND TRANSFUSION CENTERS, BY REGION, 2023-2030 ($MILLION)
TABLE 13. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2030 ($MILLION)
TABLE 14. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY REGION, 2023-2030 ($MILLION)
TABLE 15. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 16. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 17. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 18. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 19. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 20. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 21. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 22. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 23. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 24. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 25. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 26. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 27. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 28. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 29. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 30. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 31. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 32. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 33. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 34. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 35. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 36. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 37. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 38. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 39. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 40. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 41. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 42. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 43. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 44. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 45. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 46. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 47. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 48. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 49. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 50. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 51. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 52. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 53. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 54. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 55. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 56. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 57. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 58. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 59. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 60. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 61. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 62. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 63. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 64. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 65. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 66. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 67. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 68. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 69. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 70. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 71. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 75. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 76. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 77. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 78. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 79. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 80. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 81. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 82. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 83. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 84. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 85. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 86. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 87. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 88. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 89. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 90. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 91. SYSMEX CORPORATION: KEY EXECUTIVES
TABLE 92. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 93. SYSMEX CORPORATION: PRODUCT SEGMENTS
TABLE 94. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 95. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 96. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 97. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 98. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 99. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 100. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 101. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 102. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 104. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 105. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 106. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 107. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 108. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 109. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 110. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 111. EKF DIAGNOSTICS HOLDINGS PLC.: KEY EXECUTIVES
TABLE 112. EKF DIAGNOSTICS HOLDINGS PLC.: COMPANY SNAPSHOT
TABLE 113. EKF DIAGNOSTICS HOLDINGS PLC.: PRODUCT SEGMENTS
TABLE 114. EKF DIAGNOSTICS HOLDINGS PLC.: PRODUCT PORTFOLIO
TABLE 115. EKF DIAGNOSTICS HOLDINGS PLC.: KEY STRATERGIES
TABLE 116. HORIBA, LTD.: KEY EXECUTIVES
TABLE 117. HORIBA, LTD.: COMPANY SNAPSHOT
TABLE 118. HORIBA, LTD.: PRODUCT SEGMENTS
TABLE 119. HORIBA, LTD.: PRODUCT PORTFOLIO
TABLE 120. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 121. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 122. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 123. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 124. MADISON INDUSTRIES: KEY EXECUTIVES
TABLE 125. MADISON INDUSTRIES: COMPANY SNAPSHOT
TABLE 126. MADISON INDUSTRIES: PRODUCT SEGMENTS
TABLE 127. MADISON INDUSTRIES: PRODUCT PORTFOLIO
TABLE 128. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: KEY EXECUTIVES
TABLE 129. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT
TABLE 130. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT SEGMENTS
TABLE 131. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT PORTFOLIO
TABLE 132. SOULBRAIN HOLDINGS CO LTD: KEY EXECUTIVES
TABLE 133. SOULBRAIN HOLDINGS CO LTD: COMPANY SNAPSHOT
TABLE 134. SOULBRAIN HOLDINGS CO LTD: PRODUCT SEGMENTS
TABLE 135. SOULBRAIN HOLDINGS CO LTD: PRODUCT PORTFOLIO
TABLE 136. SOULBRAIN HOLDINGS CO LTD: KEY STRATERGIES
TABLE 01. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 02. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COMPLETE BLOOD COUNT (CBC), BY REGION, 2023-2030 ($MILLION)
TABLE 03. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2023-2030 ($MILLION)
TABLE 04. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HEMOGLOBIN TESTING AND ANEMIA DIAGNOSIS, BY REGION, 2023-2030 ($MILLION)
TABLE 05. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2030 ($MILLION)
TABLE 06. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 07. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR PRESCRIPTION BASED PRODUCT, BY REGION, 2023-2030 ($MILLION)
TABLE 08. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTC BASED PRODUCT, BY REGION, 2023-2030 ($MILLION)
TABLE 09. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 10. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2023-2030 ($MILLION)
TABLE 11. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023-2030 ($MILLION)
TABLE 12. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR BLOOD BANKS AND TRANSFUSION CENTERS, BY REGION, 2023-2030 ($MILLION)
TABLE 13. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2030 ($MILLION)
TABLE 14. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY REGION, 2023-2030 ($MILLION)
TABLE 15. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 16. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 17. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 18. NORTH AMERICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 19. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 20. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 21. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 22. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 23. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 24. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 25. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 26. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 27. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 28. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 29. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 30. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 31. EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 32. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 33. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 34. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 35. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 36. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 37. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 38. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 39. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 40. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 41. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 42. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 43. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 44. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 45. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 46. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 47. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 48. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 49. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 50. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 51. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 52. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 53. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 54. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 55. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 56. ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 57. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 58. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 59. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 60. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 61. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 62. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 63. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 64. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 65. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 66. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 67. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 68. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 69. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 70. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 71. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 75. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 76. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 77. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 78. LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 ($MILLION)
TABLE 79. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 80. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 81. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 82. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 83. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 84. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 85. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 86. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 87. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 88. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 ($MILLION)
TABLE 89. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023-2030 ($MILLION)
TABLE 90. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023-2030 ($MILLION)
TABLE 91. SYSMEX CORPORATION: KEY EXECUTIVES
TABLE 92. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 93. SYSMEX CORPORATION: PRODUCT SEGMENTS
TABLE 94. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 95. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 96. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 97. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 98. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 99. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 100. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 101. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 102. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 104. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 105. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 106. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 107. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 108. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 109. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 110. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 111. EKF DIAGNOSTICS HOLDINGS PLC.: KEY EXECUTIVES
TABLE 112. EKF DIAGNOSTICS HOLDINGS PLC.: COMPANY SNAPSHOT
TABLE 113. EKF DIAGNOSTICS HOLDINGS PLC.: PRODUCT SEGMENTS
TABLE 114. EKF DIAGNOSTICS HOLDINGS PLC.: PRODUCT PORTFOLIO
TABLE 115. EKF DIAGNOSTICS HOLDINGS PLC.: KEY STRATERGIES
TABLE 116. HORIBA, LTD.: KEY EXECUTIVES
TABLE 117. HORIBA, LTD.: COMPANY SNAPSHOT
TABLE 118. HORIBA, LTD.: PRODUCT SEGMENTS
TABLE 119. HORIBA, LTD.: PRODUCT PORTFOLIO
TABLE 120. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 121. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 122. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 123. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 124. MADISON INDUSTRIES: KEY EXECUTIVES
TABLE 125. MADISON INDUSTRIES: COMPANY SNAPSHOT
TABLE 126. MADISON INDUSTRIES: PRODUCT SEGMENTS
TABLE 127. MADISON INDUSTRIES: PRODUCT PORTFOLIO
TABLE 128. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: KEY EXECUTIVES
TABLE 129. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT
TABLE 130. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT SEGMENTS
TABLE 131. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT PORTFOLIO
TABLE 132. SOULBRAIN HOLDINGS CO LTD: KEY EXECUTIVES
TABLE 133. SOULBRAIN HOLDINGS CO LTD: COMPANY SNAPSHOT
TABLE 134. SOULBRAIN HOLDINGS CO LTD: PRODUCT SEGMENTS
TABLE 135. SOULBRAIN HOLDINGS CO LTD: PRODUCT PORTFOLIO
TABLE 136. SOULBRAIN HOLDINGS CO LTD: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030
FIGURE 02. SEGMENTATION OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET,2023-2030
FIGURE 03. TOP IMPACTING FACTORS IN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET (2023 TO 2030)
FIGURE 04. TOP INVESTMENT POCKETS IN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET (2024-2030)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 AND 2030(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COMPLETE BLOOD COUNT (CBC), BY COUNTRY 2023 AND 2030(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY 2023 AND 2030(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HEMOGLOBIN TESTING AND ANEMIA DIAGNOSIS, BY COUNTRY 2023 AND 2030(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 16. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023 AND 2030(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR PRESCRIPTION BASED PRODUCT, BY COUNTRY 2023 AND 2030(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTC BASED PRODUCT, BY COUNTRY 2023 AND 2030(%)
FIGURE 19. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023 AND 2030(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2030(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR BLOOD BANKS AND TRANSFUSION CENTERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 24. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET BY REGION, 2023 AND 2030(%)
FIGURE 25. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 26. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 27. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 28. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 29. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 30. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 31. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 32. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 33. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 34. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 35. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 36. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 37. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 38. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 39. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 41. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 42. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 43. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 44. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2023
FIGURE 52. SYSMEX CORPORATION: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 53. SYSMEX CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 54. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
FIGURE 55. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 56. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 57. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 59. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2022-2024 ($MILLION)
FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 62. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 63. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
FIGURE 64. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 65. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 66. EKF DIAGNOSTICS HOLDINGS PLC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 67. EKF DIAGNOSTICS HOLDINGS PLC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 68. EKF DIAGNOSTICS HOLDINGS PLC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 69. HORIBA, LTD.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 70. HORIBA, LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 71. HORIBA, LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 72. BIO-RAD LABORATORIES, INC. : NET SALES, 2022-2024 ($MILLION)
FIGURE 73. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 74. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2024 (%)
FIGURE 75. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 76. SOULBRAIN HOLDINGS CO LTD: NET SALES, 2021-2023 ($MILLION)
FIGURE 01. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030
FIGURE 02. SEGMENTATION OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET,2023-2030
FIGURE 03. TOP IMPACTING FACTORS IN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET (2023 TO 2030)
FIGURE 04. TOP INVESTMENT POCKETS IN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET (2024-2030)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 AND 2030(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COMPLETE BLOOD COUNT (CBC), BY COUNTRY 2023 AND 2030(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY 2023 AND 2030(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HEMOGLOBIN TESTING AND ANEMIA DIAGNOSIS, BY COUNTRY 2023 AND 2030(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 16. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY MODE OF PRESCRIPTION, 2023 AND 2030(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR PRESCRIPTION BASED PRODUCT, BY COUNTRY 2023 AND 2030(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTC BASED PRODUCT, BY COUNTRY 2023 AND 2030(%)
FIGURE 19. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, BY END USER, 2023 AND 2030(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2030(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR BLOOD BANKS AND TRANSFUSION CENTERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2030(%)
FIGURE 24. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET BY REGION, 2023 AND 2030(%)
FIGURE 25. U.S. POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 26. CANADA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 27. MEXICO POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 28. GERMANY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 29. FRANCE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 30. UK POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 31. ITALY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 32. SPAIN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 33. HUNGARY POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 34. REST OF EUROPE POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 35. JAPAN POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 36. CHINA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 37. INDIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 38. AUSTRALIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 39. SOUTH KOREA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 41. BRAZIL POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 42. SAUDI ARABIA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 43. SOUTH AFRICA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 44. REST OF LAMEA POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET, 2023-2030 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: POINT OF CARE HEMATOLOGY DIAGNOSTICS MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2023
FIGURE 52. SYSMEX CORPORATION: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 53. SYSMEX CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 54. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
FIGURE 55. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 56. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 57. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 59. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2022-2024 ($MILLION)
FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 62. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 63. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
FIGURE 64. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 65. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 66. EKF DIAGNOSTICS HOLDINGS PLC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 67. EKF DIAGNOSTICS HOLDINGS PLC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 68. EKF DIAGNOSTICS HOLDINGS PLC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 69. HORIBA, LTD.: NET REVENUE, 2022-2024 ($MILLION)
FIGURE 70. HORIBA, LTD.: REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 71. HORIBA, LTD.: REVENUE SHARE BY REGION, 2024 (%)
FIGURE 72. BIO-RAD LABORATORIES, INC. : NET SALES, 2022-2024 ($MILLION)
FIGURE 73. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2024 (%)
FIGURE 74. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2024 (%)
FIGURE 75. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 76. SOULBRAIN HOLDINGS CO LTD: NET SALES, 2021-2023 ($MILLION)
